INTRODUCTION {#sec0005}
============

International guidelines recommend neoadjuvant chemotherapy (NACT) for patients with muscle-invasive bladder cancer (MIBC) \[[@ref001]\]; emerging evidence suggests that adjuvant chemotherapy (ACT) provides comparable benefit \[[@ref004]\]. We have recently described practice patterns in Ontario, Canada \[[@ref006]\]. Only 6% and 22% of patients in Ontario received NACT or ACT during 1994--2008, respectively; 16% and 39% of patients were referred to MO for consideration of NACT/ACT. Similar findings have been described elsewhere \[[@ref008]\]. These data identify upstream barriers at the urologist and downstream at the MO.

Limited literature exists that identifies barriers and enablers to chemotherapy use for bladder cancer with most studies only describing self-reported practice patterns \[[@ref007]\]. A recent survey of 125 urologic oncologists found that the strongest patient factors associated with use of NACT was clinical T3/4 disease \[[@ref015]\]. The same study also found that surgeons who work at centres where medical oncologists are strong proponents of NACT are more likely to discuss this treatment option with patients. We recently undertook a qualitative study using a knowledge translation (KT) framework to identify knowledge, attitudes and beliefs among urologists, MOs and radiation oncologists (ROs) about NACT/ACT (In Press, Can Urol Assoc J). The predominant enablers to the use of chemotherapy included: the presence of chemotherapy 'champions', routine referral to MO, and system-level factors that optimize multidisciplinary care. The predominant barriers included: a lack of confidence in the magnitude of benefit associated with NACT/ACT and inadequate multidisciplinary collaboration.

Use of a knowledge translation (KT) conceptual framework can guide future intervention studies \[[@ref016]\]. The Theoretical Domains Framework (TDF) is a comprehensive framework to identify barriers and enablers of implementing evidence into practice. The TDF can facilitate design of KT interventions as it offers broad coverage of potential change pathways \[[@ref018]\].

We undertook this quantitative study to determine the prevalence of barriers and enablers among practicing urologists, MOs and ROs. Barriers and enablers identified within the relevant theoretical domains can subsequently be mapped to appropriate implementation interventions in an effort to increase chemotherapy utilization.

METHODS {#sec0010}
=======

Study design and participants {#sec0015}
-----------------------------

Results from an earlier qualitative study (In Press, Can Urol Assoc J) informed the development of a cross-sectional survey for the three specialist groups. All practicing urologists, MOs and ROs who treat patients with bladder cancer in Canada were invited to participate in the electronic survey (June 2016). The survey was distributed to all Canadian urologists and MOs/ROs that treat bladder cancer. The survey was distributed electronically using Fluid Surveys© software. A modified approach of Dillman's Total Design Method \[[@ref019]\] was used to maximize response rates. The study was approved by the Research Ethics Board of Queen's University.

Survey design and content {#sec0020}
-------------------------

Survey design was based on thematic analysis of our recently completed qualitative study. Question development was based on targeted health behaviours: (1) Are urologists referring patients to MO for NACT/ ACT?; (2) Are MOs treating patients with NACT/ACT?; and (3) Are ROs referring patients to MO for NACT/ACT if not already done by urology? The surveys included questions informed by domains of the TDF \[[@ref017]\] ([Appendix 1](#app1){ref-type="app"}) pertaining to (a) the knowledge, attitudes and beliefs of the clinicians about referral/use of NACT/ACT; and (b) the potential barriers and enablers of chemotherapy delivery. Responses to the majority of survey questions were in the form of categorical (yes/no; multiple choice) and ordinal variables (5-point Likert scale).

Questions were developed for each TDF domain. TDF domains are not mutually exclusive and thus a survey question may be mapped to more than one relevant TDF domain. Responses to ordinal survey questions were collapsed into three categories for analysis purposes: strongly disagree/disagree, neutral, strongly agree/agree. In addition, a composite summary mean score of all questions relevant to each of the identified TDF domains was created for univariate analysis \[[@ref020]\]. Higher scores are more conducive to achieving the targeted health behaviours (i.e. increased referral/use of NACT/ACT). Participants were excluded from the summary score for a given TDF domain if there were missing values on any questions within that domain. This approach was chosen since we had few study respondents with missing values (16/200 had≥1 missing value) and we could not assume responses were missing at random \[[@ref020]\].

The surveys also included questions about contraindications for chemotherapy and the presentation of a hypothetical case. Open-ended survey questions were used to ask participants about the greatest achievements and challenges in delivering chemotherapy.

The surveys were developed by a multidisciplinary team with expertise in the treatment of bladder cancer and expertise in survey methodology/implementation science.

Statistical analysis {#sec0025}
--------------------

We used the following questions to classify respondents as low or high adopters of NACT/ACT: Urologists *-- 'Of the last 10 patients that you have seen with MIBC, how many of them did you refer to medical oncology for a discussion about chemotherapy?'*; MOs -- *'Of the last 10 MIBC patients that you have seen, how many of them did you treat with NACT or ACT)?'*; ROs -- *'Of the last 10 MIBC patients that you have seen, how many would NOT already have been referred to medical oncology by urology?'*; and *'Of those MIBC patients not referred by urology, how many did you refer to medical oncology for a discussion about chemotherapy?'*. Respondents whose reported values were greater than or equal to the median were classified as high adopters. Logistic regression was used to identify TDF domains associated with high adoption of NACT/ACT referral/use in practice. Results were considered statistically significant at *p*-value \< 0.05. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

RESULTS {#sec0030}
=======

Study participants {#sec0035}
------------------

Survey response rates were 20% for urologists (110/562), 36% for MOs (47/131), and 31% for ROs (43/139). The proportion of respondents who treated \>10 MIBC patients/year were 34% (37/110 urologists), 47% (22/47 MOs), and 28% (12/43 ROs).

Case scenario and survival estimates {#sec0040}
------------------------------------

Survival estimates for a hypothetical case of a 60 year old man with clinical T3N0 MIBC are shown in [Table 1](#blc-4-blc170148-t001){ref-type="table"}. Mean overall survival at 5 years with cystectomy alone was 53%, 61% with NACT and 56% with ACT. However, as shown in [Fig. 1](#blc-4-blc170148-g001){ref-type="fig"} there is substantial variation within each specialty. Urologists, MOs and ROs reported a mean 9%, 8%, and 7% survival gain with NACT respectively; corresponding mean survival gains with ACT were 2%, 4%, and 4% respectively.

###### 

Survival estimates from urologists, medical oncologists and radiation oncologists for a hypothetical case scenario

  ESTIMATED 5 YEAR OVERALL SURVIVAL (%)                                  
  --------------------------------------- -------- ---------- ---------- ----------
  Urologists                              Mean         55         64         57
  N = 110                                 Median       50         65         55
                                          Range     (25--85)   (20--95)   (20--85)
  Medical                                 Mean         49         57         53
  Oncologists                             Median       50         57         53
  N = 47                                  Range     (10--80)   (30--90)   (20--82)
  Radiation                               Mean         51         58         55
  Oncologists                             Median       50         57         55
  N = 43                                  Range     (20--75)   (30--85)   (20--80)
  All                                     Mean         53         61         56
  Specialists                             Median       50         60         55
  N = 200                                 Range     (10--85)   (20--95)   (20--85)

^∧^A 65 year old man presents to the Emergency Room with hematuria. Cystoscopy and biopsy shows evidence of muscle-invasive urothelial carcinoma. Staging CT scan of the chest/abdomen/pelvis and bone scan do not show any evidence of metastatic disease (imaging suggests T3 N0 disease). The patient has minimal co-morbidity, normal renal function, and is willing to follow your recommendations. What treatment options would you consider recommending for this patient?

![Survival estimates for a hypothetical patient with muscle-invasive bladder cancer treated with cystectomy and/or neoadjuvant chemotherapy as reported by urologists (Panel A), medical oncologists (Panel B), and radiation oncologists (Panel C).](blc-4-blc170148-g001){#blc-4-blc170148-g001}

Identified barriers and enablers to NACT/ACT referral/use {#sec0045}
---------------------------------------------------------

Urologists reported referring a median of 9/10 patients to MO to discuss NACT/ACT. MOs reported treating a median of 7/10 patients referred for NACT/ACT. ROs reported that a median of 3/10 MIBC patients seen were not already referred to MO by urology; a median of 2/3 patients were subsequently referred to MO.

Univariate associations between TDF summary domain scores and referral/use of NACT/ACT are found in [Table 2](#blc-4-blc170148-t002){ref-type="table"}. A summary of specialist-specific survey questions and responses organized by TDF domain can be found in [Appendices 2](#app2){ref-type="app"}--[4](#app4){ref-type="app"}.

###### 

Associations between TDF domains and adoption of chemotherapy across physician specialties for patients with localized muscle-invasive bladder cancer

  TDF Domain                                   Association with "High Adopter"\* of Chemotherapy OR (95% CI) \*                            
  ------------------------------------------- ------------------------------------------------------------------ ------------------------- -------------------
  Beliefs about consequences                                        **4.87 (1.79--13.26)**                          2.40 (0.47--12.31)      0.37 (0.06--2.17)
  Memory, attention, decision-making skills                         **0.50 (0.27--0.91)**                            1.35 (0.52--3.48)      0.66 (0.19--2.24)
  Social and professional role                                     **16.50 (4.60--59.16)**                        **4.88 (1.08--22.03)**    0.40 (0.09--1.86)
  Environmental context and resources                                 1.65 (0.72--3.77)                              1.15 (0.37--3.60)      0.68 (0.22--2.11)
  Social influences                                                 **5.68 (2.41--13.37)**                        **6.55 (1.50--28.61)**           n/a
  Behavioural regulation                                                     n/a                                  **12.23 (1.98--75.59)**   1.33 (0.74--2.40)
  Knowledge                                                                  n/a                                     1.24 (0.62--2.46)             n/a
  Beliefs about capabilities                                          0.53 (0.27--1.03)                              1.25 (0.63--2.48)             n/a

\*A urologist was defined as a high adopter if they referred a median of≥9/10 MIBC patients to medical oncology for consultation. A medical oncologist was defined as a high adopter if they treated a median of≥7/10 referred MIBC patients with chemotherapy. A radiation oncologist was defined as a high adopter if they referred a median of≥2 of the last 3 patients that they had seen to medical oncology that that were not already referred by urology. OR = odds ratio. CI = confidence interval. n/a = no survey questions for the domain. Bolded values indicate statistically significant results (*p* \< 0.05).

Behaviour 1: Are urologists referring MIBC patients to MO for NACT/ ACT? {#sec0050}
------------------------------------------------------------------------

TDF domains '*beliefs about consequences*' (OR =4.9, 95% CI 1.8--13.3), '*social and professional role*' (OR = 16.5, 95% CI 4.6--59.2) and '*social influences*' (OR = 5.7, 95% CI 2.4--13.4) were all associated with higher rates of referral to MO. Within these domains we highlight pertinent questions and responses. '*Beliefs about consequences*': 89% (94/106) felt confident in the evidence supporting NACT, 82% (87/106) felt the magnitude of benefit associated with NACT is important, and 25% (27/106) were concerned about NACT delaying surgery. '*Social and professional role*': 46% (45/97) felt it was their responsibility to select which patients are eligible for chemotherapy and only refer those patients. '*Social influences*': 77% (74/96) reported that patients are generally accepting of chemotherapy. The TDF domain '*memory, attention and decision making*' was inversely associated with referral to MO (OR = 0.50, 95% CI 0.27--0.91). Forty-four percent of urologists (45/103) felt confident in determining who was a candidate for chemotherapy.

Behaviour 2: Are MOs treating MIBC patients with NACT/ACT? {#sec0055}
----------------------------------------------------------

TDF domains '*social and professional role*' (OR = 4.9, 95% CI 1.1--22.0), '*social influences*' (OR = 6.6, 95% CI 1.5--28.6) and '*behavioural regulation*' (OR = 12.2, 95% CI 2.0--75.6) were associated with increased use of NACT/ACT ([Table 3](#blc-4-blc170148-t003){ref-type="table"}). '*Social and professional role*': 74% (35/47) and 83% (39/47) reported having local urology and MO champions advocating for NACT/ACT; 38% (18/47) stated that urologists only refer patients they feel are suitable for NACT/ACT. '*Social influences*': 87% (41/47) indicated that patients were generally accepting of chemotherapy. '*Behavioural regulation*': 83% (39/47) felt that urologists routinely refer patients to MO.

###### 

Potential contraindications to neoadjuvant/adjuvant chemotherapy for muscle-invasive bladder cancer as reported by urologists, medical oncologists, and radiation oncologists

  Potential Contraindication                          Urologists (N = 106) N (%)   Medical Oncologists (N = 47) N (%)   Radiation Oncologists (N = 41) N (%)
  -------------------------------------------------- ---------------------------- ------------------------------------ --------------------------------------
  Patients \>70 years of age                                    7 (7%)                           1 (2%)                                3 (7%)
  Patients with cardiovascular disease                         15 (14%)                         13 (28%)                              10 (24%)
  Patients with peripheral neuropathy                          44 (42%)                         26 (55%)                              15 (37%)
  Patients with poor ECOG performance status (\>2)             88 (83%)                         46 (98%)                              40 (98%)
  Patients with renal insufficiency                            91 (86%)                         39 (83%)                              29 (71%)
  Patients with tinnitus                                       25 (24%)                         17 (36%)                              9 (22%)

Behaviour 3: Are ROs referring MIBC patients to MO for NACT/ACT if not already done by urology? {#sec0060}
-----------------------------------------------------------------------------------------------

Among ROs, no TDF domains were associated with increased referral of MIBC patients to MO for chemotherapy consultation ([Table 2](#blc-4-blc170148-t002){ref-type="table"}). This is likely explained by the fact that, in this study, very few patients (3/10) seen by ROs had not already been referred to MO for chemotherapy consultation.

Contraindications to chemotherapy {#sec0065}
---------------------------------

Reported contraindications to chemotherapy are shown in [Table 3](#blc-4-blc170148-t003){ref-type="table"}. Poor performance status (\>ECOG 2), renal insufficiency, and peripheral neuropathy were reported by a majority of respondents as contraindications to NACT/ACT.

System-level barriers and enablers in relation to referral/use of NACT/ACT {#sec0070}
--------------------------------------------------------------------------

The TDF domain '*environmental context and resources*' emerged as a common theme in the open-response question about the greatest achievements/challenges in delivering chemotherapy. Common themes included access to urologists/MOs with genitourinary cancer expertise, multidisciplinary bladder clinics (MBC) and case conferences (MCC); availability of nurse navigator; communication between urology and MO; and accessibility of operating room time. A substantial majority of respondents felt that having MCCs, MBCs, and a mandatory MO referral policy contributed to greater use of NACT/ACT at their centre ([Table 4](#blc-4-blc170148-t004){ref-type="table"}).

###### 

System-level enablers to the referral/use of chemotherapy among patients with muscle-invasive bladder cancer

  Survey questions related to the TDF Domain
  ------------------------------------------------------------------------------------------------------------------------------------------------
  Multidisciplinary case conferences
  Our GU multidisciplinary case conferences are helpful to discuss treatment options for patients with MIBC
    Strongly Agree/Agree
  Our GU multidisciplinary case conferences are well attended by urology
    Strongly Agree/Agree
  Our GU multidisciplinary case conferences are well attended by medical oncology
    Strongly Agree/Agree
  Our GU multidisciplinary case conferences are well attended by radiation oncology
    Strongly Agree/Agree
  Our GU multidisciplinary case conferences result in a larger proportion of MIBC patients receiving NACT/ACT.
    Strongly Agree/Agree
  Multidisciplinary bladder clinics
  Our multidisciplinary clinic for bladder cancer has resulted in more patients being treated with NACT/ACT
    Strongly Agree/Agree
  Nurse Navigator
  Our institution has a nurse navigator that helps with the patient referral system
  Yes
  Institutional Policy to ensure MIBC patients are seen by medical oncology, urology and radiation oncology
  More patients with MIBC are receiving NACT/ACT at our center since we instituted a policy that patients are to be referred to medical oncology
    Strongly Agree/Agree
  Medical Oncologists with GU expertise
  The percentage of MIBC patients at our center who get NACT/ACT increased after we obtained GU MO expertise
    Strongly Agree/Agree

\*Only participants with access to these system-level factors/resources were able to answer. For this reason the "N" for each set of questions is different. ^∧^This question was not included in the medical oncology survey. Abbreviations: TDF, Theoretical Domains Framework; GU, genitourinary; NACT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy; MIBC, muscle-invasive bladder cancer; MO, medical oncology.

Do provider beliefs guide practice? {#sec0075}
-----------------------------------

The median magnitude of benefit (i.e. absolute improvement in 5 year OS) associated with NACT was 5%. Providers who reported an estimated effect size of \>5% were more likely to be refer/deliver chemotherapy compared to providers who reported estimated effect sizes of \<5% (67% vs 46%, *p* = 0.003). Twenty-three percent of all respondents strongly agreed that magnitude of survival benefit associated with NACT is important; 62% of these providers were "adopters" of chemotherapy compared to 54% of providers who did not strongly agree (*p* = 0.334).

DISCUSSION {#sec0080}
==========

This survey explored knowledge, attitudes, and beliefs of urologists, MOs, and ROs in Canada regarding the utilization of NACT/ACT for muscle-invasive bladder cancer. The survey questions were designed using a KT framework and guided by our earlier qualitative work in semi-structured interviews. Among urologists and MOs the TDF domains *'social and professional role'* and *'social influences'* were associated with higher referral/use chemotherapy. Common enablers within these domains relate to having local champions who advocate for use of NACT/ACT, routine referral from urology to MO, and the belief that patients were generally accepting of chemotherapy. Conversely, a lack of local champions, and a perception among urologists that MOs do not treat the majority of referred patients with chemotherapy were identified as barriers. A proportion of participating urologists did not feel that it was their responsibility to refer all patients to MO and would only refer patients they deemed eligible for chemotherapy.

Factors related to *'environmental context and resources'* were consistently identified in free-text responses as primary barriers/enablers to use of chemotherapy but this domain was not found to be associated with referral/use of NACT/ACT in the univariate model. Those who did practice in settings with MBCs, nurse navigators, and mandatory MO referral felt that these system-level resources were increased utilization of NACT/ACT.

Our study also highlights a substantial disconnect between outcomes anticipated by clinicians and outcomes achieved in routine practice. The five year overall survival estimates (53% with cystectomy and 61% with NACT/cystectomy) are substantially higher than outcomes we have previously reported in the general population of Ontario (29% and 25% respectively) \[[@ref006]\]. Moreover, our data show tremendous variation in survival estimates between providers even within the same specialty. This gap between expected and actual outcomes is an area that warrants knowledge translation efforts to ensure that clinicians and patients have a clear understanding of disease prognosis. Consistent with prior literature in lung cancer, we also found that provider beliefs are associated with adoption of chemotherapy for bladder cancer \[[@ref022]\].

To our knowledge, this is the first study to evaluate clinician perceived barriers and enablers to chemotherapy for bladder cancer using a KT framework. In seeking to identify and determine the prevalence of potential barriers and enablers influencing practice, use of the TDF minimizes the risk of neglecting important factors that may not be obvious at the outset of study design. The TDF can also guide the design and development process for future KT efforts. In addition, the current study included all three physician groups who manage MIBC; this allowed us to capture each group's unique cultures, beliefs and practices.

The low overall response and selection bias may limit the generalizability of the results. The fact that 9/10 urologists referred patients for chemotherapy also suggests that the study respondents likely represent a sub-group of practitioners who have already adopted NACT. Further, due to the small sample size our statistical power was limited for the conduct of multivariable analyses. Another limitation is that our study did not consider barriers/enablers to use of NACT/ACT from the patient perspective; this will form a parallel line of inquiry in the future. Finally, in an effort to quantify the association between TDF domains and use/referral of chemotherapy we used a pooled mean score approach across all questions within a specific domain. Pooling data across related questions in one domain may obscure a particularly strong barrier/enabler that was identified in a single question; to mitigate this we also carefully evaluated free-text responses regarding the greatest challenges/successes at their centre.

Interventions that have been designed to improve the uptake of research evidence into clinical practice in other disease settings have had limited and varied effects \[[@ref023]\]. This may relate to a lack of explicit rationale for the intervention choice \[[@ref016]\]. Using a validated theoretical framework at the outset helped to ensure that our study design, conduct, and interpretation would optimize the design of a future intervention study \[[@ref016]\]. The TDF allowed us to identify barriers/enablers within each domain can be now guide selection of the most appropriate KT intervention \[[@ref025]\]. For example, in the current study negative beliefs about the consequences of referral to MO for chemotherapy consultation by urologists may be modified by using influential peer opinion leaders at local sites or provision of information regarding patient outcomes. Finally, environmental changes to facilitate behavior change including the implementation of institutional policy mandating multidisciplinary collaboration may be required.

A four-step systematic approach for the development of theory-based behavioural change interventions has been described in the literature \[[@ref016]\]. Our previous work has addressed step 1 of this process, revealing both low patterns of referral from urologists to MOs for NACT/ACT and low use of chemotherapy by MOs \[[@ref006]\]. The current study addresses step 2, identification of key barriers and enablers to the use of NACT/ACT among patients with bladder cancer. Steps 3 and 4 involve identifying, implementing, and measuring the impact of appropriate behavior change techniques; this represents a logical evolution of our research program.

In summary our study suggests that local urology and MO champions *('social and professional role')* who advocate for NACT/ACT, systems-level factors *('environmental context/resources')* that optimize multidisciplinary care, and patient engagement *('social influences')* in the discussion of treatment options are critical factors that need to be considered in any future efforts to improve utilization of chemotherapy for MIBC. Our data also demonstrate a large gap between outcomes anticipated by clinicians and outcomes observed in routine practice. This has important implications for clinicians counselling patients regarding prognosis and treatment options. Findings from this study will be useful to policy and decision makers in the research planning, implementation and evaluation process.
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###### 

Theoretical Domains Framework: Domains, Definitions and Constructs (Adapted from Cane, 2012)

  Domain
  ---------------------------------------
  Knowledge
  Skills
  Social and Professional Role
  Beliefs about capabilities
  Beliefs about consequences
  Reinforcement
  Intentions
  Goals
  Memory, attention and decision making
  Environmental context and resources
  Social Influences
  Emotion
  Behavioural regulation

###### 

Barriers and enablers to the use of chemotherapy in MIBC by TDF Domain identified by urologists

  TDF Domain
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  I am confident in the published evidence regarding the benefits of NACT in MIBC.
  I am confident in the published evidence regarding the benefits of ACT in MIBC.
  I think the magnitude of benefit with NACT is clinically important.
  I think the magnitude of benefit with ACT is clinically important.
  In absence of higher risk disease features (i.e. lymphovascular invasion, positive nodes, etc.), patients with MIBC do not benefit from NACT and should proceed directly to cystectomy.\*
  I am not sure that MIBC patients benefit from treatment with NACT.\*
  I am not sure that MIBC patients benefit from treatment with ACT.\*
  I am concerned about the delay in surgery when medical oncologists give NACT.\*
  I believe that my referral to medical oncology for chemotherapy increases the patient's likelihood of cure.
  I am concerned about toxicity from chemotherapy in MIBC patients which affects my decisions to refer to medical oncology.\*
  *Memory, attention and decision making skills*
  I feel confident determining who is and who is not a chemotherapy candidate.
  I sometimes forget that NACT/ACT is an option for my MIBC patients.\*
  *Social and professional role*
  Our centre has medical oncologists who function as NACT/ACT champions and advocate for treatment in patients with MIBC
  It is my responsibility to select which patients with MIBC are suitable chemotherapy candidates and refer only those candidates on to medical oncology.\*
  It is my responsibility to have a discussion about the role of chemotherapy with all MIBC patients.
  It is my responsibility to refer all patients with MIBC to medical oncology.
  I would not refer a MIBC patient to medical oncology if that patient is clearly not a chemotherapy candidate.\*
  Our medical oncologists treat the majority of MIBC patient referrals with chemotherapy.
  I am confident our medical oncologists treat MIBC patients appropriately.
  *Environmental context and resources*
  I have access to medical oncology which makes patient referral easy.
  In the last 3 years, more MIBC patients are receiving NACT at our centre than before.
  It is more difficult for urologists at community centres to refer patients to medical oncology than it is for urologists at comprehensive cancer centres.\*
  My institution has barriers which makes communication between urology and medical oncology difficult.\*
  There is a geographic barrier between my institution and where medical oncology is located that makes it difficult to get patients in for consultation.\*
  Our multi-disciplinary clinic for bladder cancer has resulted in more patients being treated with NACT/ACT.
  Our GU multidisciplinary case conferences are well attended by urology.
  Our GU multidisciplinary case conferences are well attended by medical oncology
  Our GU multidisciplinary case conferences are well attended by radiation oncology
  Our GU multidisciplinary case conferences are helpful to discuss treatment options for patients with MIBC.
  Q33 Our GU multidisciplinary case conferences result in a larger proportion of MIBC patients receiving NACT/ACT.
  More patients with MIBC are receiving NACT/ACT at our centre since we instituted a policy that patients are to be referred to medical oncology
  At our centre, we do not use NACT for MIBC patients.\*
  At our centre, we do not use ACT for MIBC patients.\*
  The percentage of MIBC patients at our centre who get NACT/ACT increased after we obtained GU MO expertise.
  Having access to GU medical oncologists has increased my patient referral for NACT/ACT consultation.
  *Social influences*
  My patients are generally accepting of chemotherapy as part of their treatment plan.
  Many of my MIBC patients refuse to speak with medical oncology about chemotherapy options.\*
  If a patient refuses chemotherapy, I will not encourage them further to speak with medical oncology.\*
  *Beliefs about capabilities*
  I am confident our medical oncologists treat MIBC patients appropriately.
  I am able to discuss the risks and benefits of NACT with my MIBC patients.
  I am able to discuss the risks and benefits of ACT with my MIBC patients.

Totals may exceed 100% due to rounding. \*indicates a survey question that was reversed in the domain score analysis. ^∧^Only participants with access to these system-level factors/resources were able to answer.

###### 

Barriers and enablers to the use of chemotherapy in MIBC by TDF Domain identified by medical oncologists

  TDF Domain
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  I am confident in the published evidence regarding the benefits of NACT in MIBC.
  I am confident in the published evidence regarding the benefits of ACT in MIBC.
  I think the magnitude of benefit with NACT in the setting of MIBC is clinically important.
  I think the magnitude of benefit with ACT in the setting of MIBC is clinically important.
  In absence of higher risk disease features (i.e. lymphovascular invasion, positive nodes, etc.), patients with MIBC do not benefit from NACT and should proceed directly to cystectomy.\*
  I am not sure that MIBC patients benefit from treatment with NACT.\*
  I am not sure that MIBC patients benefit from treatment with ACT.\*
  I am concerned about delaying surgery by giving MIBC patients NACT.\*
  I think that treating MIBC patients with NACT improves patient survival.
  I think that treating MIBC patients with ACT improves patient survival
  I am concerned about toxicity from chemotherapy in MIBC patients which affects my decisions to treat.\*
  *Memory, attention and decision making skills*
  I am confident that I can appropriately assess whether a patient with MIBC is medically eligible for NACT/ACT.
  *Social and professional role*
  The urologists I work with who perform cystectomy consult with me about chemotherapy options for all MIBC patients.
  Urologists I work with who perform cystectomy routinely refer patients with MIBC to medical oncology for chemotherapy consultation.
  Urologists I work with who perform cystectomy select which patients with MIBC are suitable chemotherapy candidates and refer only those candidates to medical oncology.\*
  Urologists should not refer a MIBC patient to medical oncology if that patient is clearly not a chemotherapy candidate.\*
  I treat the majority of MIBC patient referrals with NACT.
  I treat the majority of MIBC patient referrals with ACT.
  Our centre has urologists who are NACT/ACT champions and advocate for treatment in patients with MIBC.
  Our centre has medical oncologists who function as NACT/ACT champions and advocate for treatment in patients with MIBC.
  *Environmental context and resources*
  My institution has barriers which makes communication between urology and medical oncology difficult.\*
  In the last 3 years, more MIBC patients are receiving NACT at our centre than before.
  *Environmental context and resources*
  Our GU multidisciplinary case conferences are helpful to discuss treatment options for patients with MIBC
  Our GU multidisciplinary case conferences are well attended by urology
  Our GU multidisciplinary case conferences are well attended by medical oncology
  Our GU multidisciplinary case conferences are well attended by radiation oncology
  Our multidisciplinary clinic for bladder cancer has resulted in more patients being treated with NACT/ACT
  More patients with MIBC are receiving NACT/ACT at our centre since we instituted a policy that patients are to be referred to medical oncology
  The percentage of MIBC patients at our centre who get NACT/ACT increased after we obtained GU MO expertise.
  There is a geographic barrier between my institution and where the urologists are located that makes it difficult to get patients in for consultation.\*
  It is more difficult for urologists at community centres to refer patients to medical oncology than it is for urologists at comprehensive cancer centres.\*
  *Social influences*
  My patients are generally accepting of chemotherapy as part of their treatment plan.
  Many patients refuse referral to medical oncology to discuss chemotherapy options.\*
  *Behavioural regulation*
  Urologists I work with who perform cystectomy routinely refer patients with MIBC to medical oncology for chemotherapy consultation.
  I treat the majority of MIBC patient referrals with NACT.
  I treat the majority of MIBC patient referrals with ACT.
  *Knowledge*
  The urologists I work with who perform cystectomy are knowledgeable about the use of NACT/ACT for MIBC patients.
  The urologists I work with who perform cystectomy consult with me about chemotherapy options for all MIBC patients.
  *Beliefs about capabilities*
  The urologists I work with who perform cystectomy are knowledgeable about the use of NACT/ACT for MIBC patients.

Totals may exceed 100% due to rounding. \*indicates a survey question that was reversed in the domain score analysis. ^∧^Only participants with access to these system-level factors/resources were able to answer.

###### 

Barriers and enablers to the use of chemotherapy in MIBC by TDF Domain identified by radiation oncologists

  TDF Domain
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  I am confident in the published evidence regarding the benefits of NACT in MIBC.
  I am confident in the published evidence regarding the benefits of ACT in MIBC.
  I think the magnitude of benefit with NACT is clinically important.
  I think the magnitude of benefit with ACT is clinically important.
  I believe that my referral to medical oncology for chemotherapy increases the patient's likelihood of cure.
  Urologists I work with who perform cystectomy are not confident that patients with MIBC benefit from NACT.\*
  Urologists I work with who perform cystectomy are not confident that patients with MIBC benefit from ACT.\*
  Urologists I work with who perform cystectomy think that in absence of higher risk disease features (i.e. lymphovascular invasion, positive nodes, etc.), patients with MIBC do not benefit from NACT and should proceed directly to cystectomy.\*
  The urologists I work with who perform cystectomy are concerned that referral to medical oncology delays surgery. \*
  *Memory, attention and decision making skills*
  I feel confident determining who is and who is not a chemotherapy candidate.
  Even if I am confident that an MIBC patient is not eligible for NACT/ACT I still refer to medical oncology for the discussion if not referred by urology.
  *Social and professional role*
  It is my responsibility to refer all patients with MIBC to medical oncology if not done so by urology
  Urologists I work with who perform cystectomy do not routinely refer MIBC patients to medical oncology for chemotherapy consultation.
  It is my responsibility to select which patients with MIBC are suitable chemotherapy candidates and refer only those candidates to medical oncology.\*
  Our centre has urologists who are NACT/ACT champions and advocate for chemotherapy in patients with MIBC.
  Our centre has medical oncologists who are NACT/ACT champions and advocate for chemotherapy in patients with MIBC
  *Environmental context and resources*
  There are communication barriers between radiation oncology and medical oncology at our centre.\*
  There are communication barriers between radiation oncology and urology at our centre.\*
  There are communication barriers between urology and medical oncology at our centre.\*
  In the last 3 years, more MIBC patients are receiving NACT at our centre than before.
  Our multidisciplinary case conferences are helpful to discuss treatment options for patients with MIBC
  *Environmental context and resources*
  Our multidisciplinary case conferences are well attended by urology
  Our multidisciplinary case conferences are well attended by medical oncology
  Our multidisciplinary case conferences are well attended by radiation oncology
  Our multidisciplinary case conferences result in a larger proportion of MIBC patients receiving NACT/ACT
  Our multidisciplinary clinic for MIBC patients has resulted in more patients being treated with NACT/ACT
  More patients with MIBC are receiving NACT/ACT at our centre since we instituted a policy that patients are to be seen by medical oncology
  The percentage of MIBC patients at our centre who get NACT/ACT increased after we obtained GU MO expertise
  Having access to GU medical oncologists has increased my patient referral for NACT/ACT consultation.
  *Behavioural regulation*
  Urologists I work with who perform cystectomy do not routinely refer MIBC patients to medical oncology for chemotherapy consultation.

Totals may exceed 100% due to rounding. \*indicates a survey question that was reversed in the domain score analysis. ^∧^Only participants with access to these system-level factors/resources were able to answer.
